Post-transplant biliary complications using liver grafts from deceased donors older than 70 years: Retrospective case-control study

Table 3 Perioperative variables and morbidity/mortality

Variables	BC (n = 21)	Non-BC (n = 229)	P value
Biliary reconstruction, n (%)
Chol-Chol-without T-tube	16 (76.2)	212 (86.9)	0.013
Chol-Chol-with T-tube	3 (14.3)	11 (4.8)
RYHJ	2 (9.5)	6 (2.6)
Transfusion (units)
Packed red blood cells	7 ± 10	5 ± 8	0.147
Fresh frozen plasma	9 ± 12	10 ± 10	0.647
Platelets	1 ± 1	1 ± 3	0.100
Initial immunosuppression, n (%)
Tacrolimus + steroids	20 (95.2)	199 (86.9)	0.231
Cyclosporine + steroids	1 (4.8)	30 (9.8)
Early allograft dysfunction	4 (19.0)	32 (14.0)	0.357
Acute renal failure	5 (23.8)	54 (13.1)	0.581
Non-surgical related infections	6 (28.6)	30 (13.1)	0.062
Acute rejection	6 (28.6)	54 (23.6)	0.608
HCV recurrence	1 (4.8)	43 (18.8)	0.085
HCC recurrence	0	9 (3.9)	0.446
Non-biliary related reoperation	1 (4.8)	12 (5.2)	0.701
Re-transplantation	0	6 (2.8)	0.643
ICU stay (d)	4 ± 5	4 ± 4	0.559
Hospital stay (d)	15 ± 13	12 ± 10	0.326
Patient follow-up (mo)	46 ± 56	72 ± 95	0.099
Overall mortality rate, n (%)	6 (28.6)	89 (38.9)	0.352
Causes of death, n (%)
Cardiovascular disease	1 (4.8)	20 (8.7)	0.041
Infections	4 (19.0)	12 (5.2)
Malignancies	1 (4.8)	23 (10)
HCV recurrence	0	13 (5.7)
Other	0	21 (9.3)

BC: Biliary complications; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; ICU: Intensive care unit; RYHJ: Roux-en-Y hepaticojejunostomy.